ClinicalTrials.gg
CompletedNCT01079832Updated Nov 28, 2013Results posted

Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies

A Phase 2 interventional study of stereotactic radiosurgery and quality-of-life assessment in Fallopian Tube Cancer, Ovarian Sarcoma and Ovarian Stromal Cancer, sponsored by Case Comprehensive Cancer Center. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-28.

Sponsored by Case Comprehensive Cancer Center · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 589 studies in Fallopian Tube Neoplasms with a site in United States — 63 open to participants now, 130 under way, 24 of them phase 3. Fallopian Tube Neoplasms · United States.

Enrollment
220th of 513
50 · median 40
Started
2009
with 20 others
Phase 2
211 of 589
20 open now
Registered
207th of 589
by date

Among the 589 studies in Fallopian Tube Neoplasms with a site in United States, this one is the 220th largest by enrollment of the 513 interventional ones that give a count, is one of 21 that started in 2009, is one of 211 in phase 2, and was the 207th registered.

Fallopian Tube Neoplasms

835 studies on the registry are indexed under Fallopian Tube Neoplasms; 131 are open to participants now.

Browse Fallopian Tube Neoplasms studies →

Open to participants now

63 of the 589 studies in Fallopian Tube Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 106 Fallopian Tube Neoplasms studies recruiting now, 88 (83%) set no upper age limit and 10 (9%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 589 studies in Fallopian Tube Neoplasms with a site in United States, or all of them as a file.
02

Study summary

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

PURPOSE: This clinical trial studies stereotactic radiosurgery using CyberKnife works in treating women with advanced or recurrent gynecological malignancies.

Read the detailed description

PRIMARY OBJECTIVES:

I. The primary goal of this study is to estimate the rate of grade 3 or higher acute toxicities observed during a 6 month period following CyberKnife radiosurgery for gynecologic cancers.

II. To evaluate clinical response to radio-surgery for gynecologic tumors.

III. To assess general and site specific quality of life (using SF-12, FACT-En, FACT-O, FACT-Cx or FACT-V) and to evaluate patient's level of pain.

SECONDARY OBJECTIVES:

I. As a secondary objective, toxicities during the 2 years following CyberKnife radiosurgery will also be described.

OUTLINE:

Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.

After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.

03

Conditions studied

  • Fallopian Tube Cancer
  • Ovarian Sarcoma
  • Ovarian Stromal Cancer
  • Recurrent Cervical Cancer
  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Epithelial Cancer
  • Recurrent Ovarian Germ Cell Tumor
  • Recurrent Uterine Sarcoma
  • Recurrent Vaginal Cancer
  • Recurrent Vulvar Cancer
  • Stage III Cervical Cancer
  • Stage III Endometrial Carcinoma
  • Stage III Ovarian Epithelial Cancer
  • Stage III Ovarian Germ Cell Tumor
  • Stage III Uterine Sarcoma
  • Stage III Vaginal Cancer
  • Stage III Vulvar Cancer
  • Stage IV Endometrial Carcinoma
  • Stage IV Ovarian Epithelial Cancer
  • Stage IV Ovarian Germ Cell Tumor
  • Stage IV Uterine Sarcoma
  • Stage IV Vulvar Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Vaginal Cancer
  • Stage IVB Cervical Cancer
  • Stage IVB Vaginal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven gynecologic
  • No prior cryosurgery or radiofrequency ablation, in target lesion
  • Patient is able to give and sign study specific
  • , according to criteria
  • Laboratory parameters and appropriate clearance from anesthesia based on other medical co-morbidities for placement of fiducials; these would include CBC, basic metabolic panel, BUN, and creatinine
  • >= 4 weeks from previous treatment (chemotherapy or radiation) of malignancy
  • performance status of 0-3 as this procedure is minimally invasive and considered palliative in these patients

Exclusion criteria

Exclusion

  • Any patient with active connective tissue disease such as lupus or dermatomyositis is excluded
  • Any patient with active Crohn's disease or active ulcerative colitis is excluded
  • Major medical or psychiatric illness, which would prevent completion of treatment or interfere with follow-up is excluded
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Arm I: CyberKnife Radiosurgery

    Patients undergo 3 fractions of CyberKnife stereotactic radiosurgery.

    Radiation: stereotactic radiosurgery · Procedure: quality-of-life assessment

Interventions

  • Radiationstereotactic radiosurgery

    Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist

  • Procedurequality-of-life assessment

    Ancillary studies

    Also known as: quality of life assessment

06

What researchers measure

Primary outcomes

  1. Acute Toxicity Rate

    The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.

    Time frame: at 6 months after treatment

Secondary outcomes

  1. Disease-free Survival

    Median disease free survival

    Time frame: completion of study at 24 months

  2. Median Overall Survival

    Length of time patients survived at study end.

    Time frame: 24 months

  3. Quality of Life

    Time frame: After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.

  4. Clinical Response Rate

    Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).

    Time frame: at 6 months from study entry

07

Results

Posted Nov 28, 2013

Participant flow

Between July 24,2009 and September 7, 2011, 50 patients were recruited from University Hospitals in Cleveland Ohio.

Participant flow — Overall Study
MilestoneArm I: CyberKnife Radiosurgery
Started50
Completed49
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryAcute Toxicity Rate

The incidence of grade 3 or 4 possible SBRT-related non-hematological toxicities observed during a 6 month period.

Time frame:
at 6 months after treatment
Reported as:
Number · percentage of participants
Acute Toxicity Rate
percentage of participantsArm I: CyberKnife Radiosurgery
Acute Toxicity Rate6
SecondaryDisease-free Survival

Median disease free survival

Time frame:
completion of study at 24 months
Reported as:
Median · months
Disease-free Survival
monthsArm I: CyberKnife Radiosurgery
Disease-free Survival7.8 (4 to 11.6)
SecondaryMedian Overall Survival

Length of time patients survived at study end.

Time frame:
24 months
Reported as:
Median · months
Median Overall Survival
monthsArm I: CyberKnife Radiosurgery
Median Overall Survival20.2 (10 to 29.5)
SecondaryQuality of Life
Time frame:
After completion of study treatment, patients are followed at 1, 3, 6, 12, 18 and 24 months.

No measurements were reported for this outcome.

SecondaryClinical Response Rate

Percentage of patients with a clinical response following RECIST (Response Evaluation Criteria in Solid Tumors) Criteria: Confirmed complete response(CR), Stable disease (SD), partial response (PR), or without progressive disease (PD).

Time frame:
at 6 months from study entry
Reported as:
Number · percentage of participants
Clinical Response Rate
percentage of participantsArm I: CyberKnife Radiosurgery
Clinical Response Rate68 (53 to 80)

Adverse events

Collected over Adverse events were collected while patients were receiving treatment and during 6 months of follow up.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm I: CyberKnife Radiosurgery—3/50 (6%)34/50 (68%)
Most frequent serious events
Most frequent serious events
EventArm I: CyberKnife Radiosurgery
Death not associated with CTCAE term - Disease progression NOSGeneral disorders1/50
Bilirubin (hyperbilirubinemia)Investigations1/50
ConfusionNervous system disorders1/50
Most frequent other events
Showing 10 of 12
Most frequent other events
EventArm I: CyberKnife Radiosurgery
"Fatigue (asthenia, lethargy, malaise)"General disorders10/34
HemoglobinBlood and lymphatic system disorders6/34
NauseaGastrointestinal disorders6/34
PlateletsBlood and lymphatic system disorders3/34
DiarrheaGastrointestinal disorders3/34
Pain - BackMusculoskeletal and connective tissue disorders3/34
AnorexiaMetabolism and nutrition disorders2/34
Pain - Abdomen NOSGastrointestinal disorders2/34
Edema: limbGeneral disorders2/34
CreatinineMetabolism and nutrition disorders2/34

Baseline characteristics

Age Continuous
Age Continuous(years)Arm I: CyberKnife Radiosurgery
Median66 (27 to 82)
Sex: Female, Male
Sex: Female, Male(Participants)Arm I: CyberKnife Radiosurgery
Female50
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm I: CyberKnife Radiosurgery
Hispanic or Latino0
Not Hispanic or Latino48
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm I: CyberKnife Radiosurgery
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White45
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Arm I: CyberKnife Radiosurgery
United States50
08

Study locations

1 site
  • Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
    Cleveland, Ohio 44106, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2010
First posted
Mar 3, 2010
Start
May 2009
Primary completionActual
May 2012
CompletionActual
May 2012
Results first posted
Nov 28, 2013
Last update
Nov 28, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01079832
Responsible party
Sponsor
First posted
Mar 3, 2010
Start date
May 2009
Primary completion
May 2012
Completion
May 2012
Results posted
Nov 28, 2013
Last update
Nov 28, 2013

Study contacts

Robert DeBernardo, MD
principal investigator · Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion